title: [Detection of serum DKK1 in multiple myeloma and myeloma bone disease].
abstract: OBJECTIVE
  To study the association between the level of serum DKK1 and disease course of multiple myeloma（MM）as well as myeloma bone disease.
  
  
  METHODS
  This study enrolled 145 cases of MM（including 79 newly diagnosed MM, 19 responded MM, 47 relapsed or progressive MM） whose lytic bone disease were evaluated by conventional radiography, ELISA was used to detect the concentration of serum DKK1.
  
  
  RESULTS
  Serum DKK-1 elevated in newly diagnosed MM compared with normal donors［2 155（646-35 251）vs 1 487（646-2 577） ng/L, P=0.000］, those responded［1 136（431- 3 582） ng/L, P=0.001］and relapsed/progressive MM［1 695（431-3 582） ng/L, P=0.037］, and the level of relapsed/progressive MM was marginally higher than the responded ones. Moreover, MM patients without lytic lesions in conventional radiography had significantly lower DKK- 1 levels than those with lytic bone disease［1 910（660-26 925）vs 2 519（646-35 251） ng/L, P=0.005］. Notably serum DKK-1 correlated with the number of bone lesions［0 vs 1-3 vs >3 lesions: 1 910（660-26 925）vs 2 155（1 369-5 974）vs 2 547（646-35 251）ng/L, P=0.018].
  
  
  CONCLUSIONS
  DKK-1 serum concentration correlated with disease course of MM and myeloma bone disease, indicating that DKK-1 was an important factor for the extent of bone disease, which supporting the hypothesis of DKK-1 as a therapeutic target in myeloma bone disease.
authors.affiliation: Department of Lymphoma and Myeloma, Institute of Hematology & Blood Diseases Hospital, Tianjin 300020, China.
authors.forename: Xiaoyan
authors.initials: X
authors.lastname: Feng
authors.affiliation: Department of Lymphoma and Myeloma, Institute of Hematology & Blood Diseases Hospital, Tianjin 300020, China.
authors.forename: Shuhui
authors.initials: S
authors.lastname: Deng
authors.affiliation: Department of Lymphoma and Myeloma, Institute of Hematology & Blood Diseases Hospital, Tianjin 300020, China.
authors.forename: Gang
authors.initials: G
authors.lastname: An
authors.affiliation: Department of Lymphoma and Myeloma, Institute of Hematology & Blood Diseases Hospital, Tianjin 300020, China.
authors.forename: Xiaoqi
authors.initials: X
authors.lastname: Qin
authors.affiliation: Department of Lymphoma and Myeloma, Institute of Hematology & Blood Diseases Hospital, Tianjin 300020, China.
authors.forename: Weiwei
authors.initials: W
authors.lastname: Sui
authors.affiliation: Department of Lymphoma and Myeloma, Institute of Hematology & Blood Diseases Hospital, Tianjin 300020, China.
authors.forename: Dehui
authors.initials: D
authors.lastname: Zou
authors.affiliation: Department of Lymphoma and Myeloma, Institute of Hematology & Blood Diseases Hospital, Tianjin 300020, China.
authors.forename: Lugui
authors.initials: L
authors.lastname: Qiu
authors.affiliation: Department of Lymphoma and Myeloma, Institute of Hematology & Blood Diseases Hospital, Tianjin 300020, China.
authors.forename: Yan
authors.initials: Y
authors.lastname: Xu
mesh_terms: D001859:Bone Neoplasms; D004797:Enzyme-Linked Immunosorbent Assay; D006801:Humans; D009101:Multiple Myeloma